NICE Throws AZ's Lynparza A Bone
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, may decide after all to recommend AstraZeneca's PARP inhibitor Lynparza (olaparib) as a maintenance treatment for a subset of NHS patients with maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer. If it sees the right evidence, it says it may be able to use flexibilities to consider more expensive treatments.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.